The FDA has issued a safety alert regarding the use of unapproved potassium phosphates drug products by Hospira in pediatric patients. These products may result in daily aluminum exposures exceeding recommended limits, potentially leading to various health issues. To prevent this, the FDA recommends using alternative products such as Fresenius Kabi’s or CMP Development’s Potassium Phosphates Injections, which have acceptable aluminum content levels. The FDA has requested that Hospira update their labeling to reflect the risk of aluminum toxicity in pediatric patients. It is important to be cautious when administering intravenous phosphorus replacement products to pediatric patients to avoid harmful aluminum exposures.
Source link
Avoid Unapproved Potassium Phosphates Injection in Pediatric Patients
